🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Clinical Trial Protocol for VIOLET Terbium-161 PSMA Phase I/II now online JNM Tb-161: Auger and conversion electrons that deposit a higher concentration of radiation over a shorter path, particularly to single tumor cells and micrometastases.

Our review article on ARPI + PARPi in #ProstateCancer now out in Springer Nature Drugs journal. Led by super ⭐️ Louise Kostos Weblink:👇 rb.gy/0oqqrn Ben Tran Peter Mac Cancer Centre University of Melbourne

☢ UpFrontPSMA "Live #ESMO24": Lutetium-177 PSMA-617 followed by docetaxel improved anti-tumour activity in men with new diagnosis of metastatic hormone-sensitive prostate cancer compared with docetaxel alone, without increased side effects 🔥Hot off the press The Lancet Oncology:

Huge news for #ProstateCancer - TALAPRO-2 trial shows sig ⬆️ in OS in all-comers & HRR-mutated pts with 1st-line mCRPC treated with Talazoparib + Enzalutamide (vs Enzalutamide). A major landmark as the 1st trial of a PARPi + ARPi to ⬆️ OS!

Novel Radiopharmaceuticals and Future of Theranostics in Genitourinary Cancers in European Urology authors.elsevier.com/c/1jyul14kplyz… Thanks Dr Martina Sollini Ospedale San Raffaele and co-authors: Jeremie Calais Louise Emmett prof. Stefano Fanti Ken Herrmann Thomas Hope Brian Shuch, MD

Thrilled to lead this transformative project to accelerate development of novel radiotracers for PET scanning and therapy! Thank-you Australian Cancer Research Foundation University of Melbourne Australian National Imaging Facility @ocrfaustralia GE HealthCare Collaborators Linda Mileshkin Luc Furic Mohammad Haskali Ken Herrmann Price Jackson

Devaki Surasi presents on combination trials with Lutetium-177 ... So many Aussie trials! ASCO #GU25 ProsTIC

AlphaBet trial of combo Lutetium-177 PSMA + Radium-223 being highlighted ... now fully retired and in follow-up period. ASCO #GU25 pubmed.ncbi.nlm.nih.gov/36465905/ Bayer | Pharmaceuticals ProsTIC PCF Science James Buteau Louise Kostos Arun Azad

Proud to share that our collaborative review on Combination Therapies in Locally Advanced PC and mHSPC is now available in European Urology authors.elsevier.com/sd/article/S03…. Thanks to this wonderful team, especially to Arun Azad and Karim Fizazi. So honoured to be involved!

We're thrilled to announce a major milestone in our first-in-human "VIOLET" study of ☢TERBIUM-161 PSMA for prostate cancer! Not only have we seen no dose-limiting toxicities across 6 cycles up to 7.4 GBq in 30 patients treated to date, but we also wrapped up recruitment more

Hot of the press in JNM ... with 10 years experience in Lutetium-177 PSMA radioligand therapy we describe a 1.3% incidence of myelodysplasia. We deep dive on each case with remarkable findings. One patient who participated in the ANZUP #TheraP trial had

LuCab Clinical Trial protocol now online JNM ANZUP #TheraP assessed Lu-177 PSMA-617 versus cabazitaxel LuCab assesses Lu-177 PSMA-617 in combination with cabazitaxel jnm.snmjournals.org/content/early/… Congrats Louise Kostos, our medical oncology PhD leading this

BREAKING NEWS🎉 Peter Mac Research researchers awarded $21M in NHMRC funding, including #prostic Director Michael Hofman! Prof. Hofman's research will incorporate new radioactive tumour seeking molecules, whole body scanning and AI for #prostatecancer clinical trials and treatments☢️

“Unravelling PSMA Biology” WEBINAR 👉Live, Free & Interactive: link.prostic.org/webinar PSMA Theranostics is booming and it is only the beginning. Let’s unravel PSMA biology together. Join us for a free and an enlightening live session with world-renowned experts. Explore the

New Frontiers in PSMA Radioligand Therapy Is this the "hottest" session at ASCO #ASCO25 ?? ■ VIOLET: First-in-human trial of Terbium-161 ■ BULLSEYE: Lu-PSMA in oligo-metastatic disease ■ ENZA-p: Biomarkers ProsTIC PCF Science

Stunning research from Edmond Kwan on ctDNA in theranostics: 🧬Low ctDNA predicts better response with ¹⁷⁷Lu-PSMA-617 vs. cabazitaxel chemotherapy ⚠️PTEN alterations linked to worse outcomes on cabazitaxel 🧪ATM defects tied to favorable PSMA-617 results 🩻PET quantitative

On the eve of #ASCO25, I am delighted to share results from the correlative analyses of the ANZUP phase II TheraP study, now published in Nature Medicine. Massive effort supported by dedicated co-investigators, coordinators, patients & families from 11 study sites across

Don't miss the first-in-human VIOLET study being presented #ASCO25 ASCO Monday June 2 3:00 PM New Frontiers in Prostate-Specific Membrane Antigen Radioligand Therapy (awesome research being presented in this session - don't miss the other talks) In press The Lancet Oncology

#VIOLET Study of Terbium-161 (Tb-161) Beta/Auger therapy ASCO #ASCO25 First prospective trial of Terbium-161 in any tumour type 🟣 30 patient trial in prostate cancer. No dose limiting toxicities at highest level of radioactivity (7.4 GBq) 🟣 Very few side effects: 1 grade 3

#VIOLET Study of Terbium-161 (161Tb) - first trial of Beta/Auger therapy. Recently presented #ASCO25. Now out in The Lancet Oncology : thelancet.com/journals/lanon… 🟣 30 patient trial in prostate cancer. No dose limiting toxicities at highest level of radioactivity (7.4 GBq) 🟣Very few